Australian biotech market today 16.03.09
Monday, 16 March, 2009
Pharma and biotech stocks were up 1 per cent at 3pm, compared to a minimal rise in the All Ordinaries.
Cochlear (ASX:COH) was up $1 to $49.91 per share following an excellent half-year report, which showed total revenues increased by 19 per cent and sales were up 22 per cent.
CSL (ASX:CSL) was up 38c to $33.38, and the last of the Big Three, Resmed (ASX:RMD) was down 10c.
Sonic Healthcare (ASX:SHL) is up a healthy 50c while Avexa (ASX:AVX) is up 16 per cent to 8c a share following good news from its Phase IIb trial of apricitabine in HIV patients.
Alchemia (ASX:ACL) is up another cent to 24c and Biota (ASX:BTA) is up slightly.
Biotron (ASX:BIT), a spin-out from ANU’s John Curtin School of Medical Research which is in early phase trials for an anti-viral for hepatitis C, is down 1c. Biotron was hit hard by the cancellation of the Commercial Ready scheme and is in the middle of a capital raising scheme.
Novogen (ASX:NRT) was up 4c to recover last week’s loss. ChemGenex (ASX:CXS) was down slightly to 43c, while Cytopia (ASX:CYT), Healthscope (ASX:HSP) and Phosphagenics (ASX:POH) were up slightly.
Life Therapeutics (ASX:LFE) is worth lolly money at 5c a share.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
